However, a recent report by Tsai et al. reported a case of aPCC-induced atypical hemolytic uremic syndrome which was successfully treated with the anti-C5 antibody eculizumab, thereby relating aPCC with terminal activation of the complement system46; further studies might clarify this potential relationship. The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.